⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
AKBA News
Akebia Therapeutics, Inc.
Akebia Therapeutics Announces First Patient Dosed in Phase 2 Basket Trial of Ebribafusp in Rare Complement-Mediated Kidney Diseases
globenewswire.com
AKBA
Focal Segmental Glomerulosclerosis (FSGS) Market Insights, Epidemiology and Forecast 2026-2036 - Targeted Therapies Reshape Treatment Through 2036
globenewswire.com
TARA
AMTX
AKBA
APLS
NVS
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AKBA
Akebia Therapeutics to Conduct Investor Meetings at the 2026 Wells Fargo Healthcare Conference in Boston
globenewswire.com
AKBA
Valeris Welcomes Patient Services Veteran Lauren Cole to Lead Commercial Strategy
prnewswire.com
MRK
ARDX
AKBA
The Galien Foundation Announces 2026 Prix Galien USA Nominees for "Best Biotechnology Product," "Best Pharmaceutical Product," and "Best Product for Rare/Orphan Diseases"
prnewswire.com
ALNY
ARQT
IONS
JAZZ
JNJ
MRK
PFE
AKBA
ARDX
BMY
BIIB
GILD
INSM
NVS
AGIO
BBIO
CRNX
GERN
KAVL
Form 8-K
sec.gov
AKBA
Akebia Therapeutics Reports Second Quarter 2026 Financial Results and Business Highlights
globenewswire.com
AKBA
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
AKBA
Akebia Therapeutics Announces Initiation of a Phase 2 Basket Trial to Study Ebribafusp, a Next-Generation Complement Inhibitor in Rare Kidney Diseases
globenewswire.com
AKBA